SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-082071
Filing Date
2024-03-29
Accepted
2024-03-29 16:12:56
Documents
15
Period of Report
2024-03-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d819653d8k.htm   iXBRL 8-K 26450
2 EX-5.1 d819653dex51.htm EX-5.1 4418
3 EX-10.1 d819653dex101.htm EX-10.1 236134
  Complete submission text file 0001193125-24-082071.txt   463617

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vinc-20240329.xsd EX-101.SCH 2839
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20240329_lab.xml EX-101.LAB 18738
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20240329_pre.xml EX-101.PRE 11700
18 EXTRACTED XBRL INSTANCE DOCUMENT d819653d8k_htm.xml XML 3767
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

IRS No.: 833197402 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39244 | Film No.: 24804246
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)